Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy.
Hylek
Elaine M
EM
Becker
Richard C
RC
D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020767:Intracranial Thrombosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D010641:Phenotype; D018570:Risk Assessment; D020521:Stroke / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors / Q000378:metabolism
D000925:Anticoagulants; D014812:Vitamin K